Tyrosine-protein phosphatase non-receptor type 2(PTPN2), an important member of the protein tyrosine phosphatase family, can regulate various signaling pathways and biological processes by dephosphorylating receptor protein tyrosine kinases. Accumulating evidence has demonstrated that PTPN2 is involved in the occurrence and development of atherosclerotic cardiovascular disease. Recently, it has been reported that PTPN2 exerts an anti-atherosclerotic effect by regulating vascular endothelial injury, monocyte proliferation and migration, macrophage polarization, T cell polarization, autophagy, pyroptosis, and insulin resistance. In this review, we summarize the latest findings on the role of PTPN2 in the pathogenesis of atherosclerosis to provide a rationale for better future research and therapeutic interventions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475599 | PMC |
| http://dx.doi.org/10.3389/fphar.2023.1219690 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engineering hydrogen bonding at tyrosine-201 in the orange carotenoid protein using halogenated analogues.
Photosynth Res
January 2025
Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
The Orange Carotenoid Protein (OCP) is a unique water-soluble photoactive protein that plays a critical role in regulating the balance between light harvesting and photoprotective responses in cyanobacteria. The challenge in understanding OCP´s photoactivation mechanism stems from the heterogeneity of the initial configurations of its embedded ketocarotenoid, which in the dark-adapted state can form up to two hydrogen bonds to critical amino acids in the protein's C-terminal domain, and the extremely low quantum yield of primary photoproduct formation. While a series of experiments involving point mutations within these contacts helped us to identify these challenges, they did not resolve them.
View Article and Find Full Text PDFA rationale for the poor response to alectinib in a patient with adenocarcinoma of the lung harbouring a fusion by artificial intelligence and molecular modelling: a case report.
Transl Lung Cancer Res
December 2024
Department of Physics and Center for Complexity and Biosystems, Università degli Studi di Milano and INFN, Milano, Italy.
Background: Non-small cell lung cancers (NSCLCs) with fusions are effectively treated with tyrosine kinase inhibitors (TKIs). The widespread use of next-generation sequencing (NGS) assays to study the molecular profile of NSCLCs, can identify rare fusion partners of . Therapy decisions are made without considering which fusion partner is present and its potential oncogenic properties.
View Article and Find Full Text PDFEGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAF mutation: a multi-center real-world experience in China.
Transl Lung Cancer Res
December 2024
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: The combination therapy of the B-Raf proto-oncogene (BRAF) inhibitor dabrafenib and the mitogen-activated protein kinase kinase (MEK) inhibitor Trametinib has shown favorable outcomes in patients initially identified with BRAF mutations. However, there are currently no large-scale study data focusing on the use of a triple therapy regimen of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) plus dabrafenib and trametinib in patients with newly concomitant BRAF mutations after acquiring resistance to EGFR-TKIs. Our study aimed to explore the efficacy and safety of the triple therapy regimen through a multi-center real-world experience.
View Article and Find Full Text PDFModification-specific Proteomic Analysis Reveals Cysteine S-Palmitoylation Involved in Esophageal Cancer Cell Radiation.
ACS Omega
January 2025
Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou 225300, China.
This study aimed to investigate the effects of radiation (RT) on protein and protein S-palmitoylation levels in esophageal cancer (EC) cell lines. EC cells ( = 6) were randomly divided into RT and negative control. The results revealed that 592 proteins were identified in the RT group, including 326 upregulation proteins and 266 downregulation proteins.
View Article and Find Full Text PDFThe roles of pleiotrophin in brain injuries: a narrative review of the literature.
Ann Med
December 2025
Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Background: Pleiotrophin (PTN), a secreted multifunctional growth factor, is highly expressed in the developing brain. Recently, many studies have indicated that PTN participates in the development of brain and plays a neuroprotection after brain injury, especially promoting neuronal survival and neurite outgrowth, stimulating oligodendrocyte maturation and myelination, modulating neuroinflammation, and so on.
Objective: However, no reviews comprehensively summarize the roles of PTN in brain injuries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!